Swedbank AB Raises Holdings in DexCom, Inc. $DXCM

Key Points

• Swedbank AB has increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 3.4%, owning approximately 0.06% of the company valued at around $20.4 million after acquiring an additional 7,589 shares.
• Several institutional investors, including Golden State Wealth Management and Private Trust Co. NA, have significantly increased their holdings in DexCom, with hedge funds and institutions owning 97.75% of the company's stock.
• DexCom reported earnings surpassing estimates with a revenue increase of 15.2% year-over-year, demonstrating strong financial growth amidst a favorable market outlook from analysts who largely rate the stock as a "Moderate Buy."

Swedbank AB raised its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 3.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 233,542 shares of the medical device company's stock after purchasing an additional 7,589 shares during the quarter. Swedbank AB owned 0.06% of DexCom worth $20,386,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Golden State Wealth Management LLC grew its stake in shares of DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares during the last quarter. Zions Bancorporation National Association UT purchased a new position in DexCom during the first quarter valued at $27,000. Heck Capital Advisors LLC bought a new position in DexCom in the 4th quarter worth about $38,000. Anderson Financial Strategies LLC bought a new stake in shares of DexCom during the first quarter valued at approximately $37,000. Finally, Alpine Bank Wealth Management purchased a new position in shares of DexCom in the first quarter worth $40,000. Institutional investors own 97.75% of the company's stock.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 1,466 shares of the business's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the transaction, the executive vice president directly owned 105,223 shares in the company, valued at $8,417,840. The trade was a 1.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director owned 51,121 shares of the company's stock, valued at $4,143,868.26. This represents a 5.10% decrease in their position. The disclosure for this sale can be found here. Insiders sold 8,315 shares of company stock valued at $689,431 in the last ninety days. Insiders own 0.32% of the company's stock.

DexCom Stock Performance

DexCom stock traded down $0.26 during midday trading on Tuesday, hitting $69.26. The stock had a trading volume of 2,160,504 shares, compared to its average volume of 4,110,610. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25. The company has a market capitalization of $27.16 billion, a PE ratio of 48.12, a P/E/G ratio of 1.41 and a beta of 1.48. The firm's fifty day moving average is $79.59 and its two-hundred day moving average is $78.19. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company's revenue was up 15.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on DXCM. Wall Street Zen cut shares of DexCom from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 10th. Mizuho upped their price objective on DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. Canaccord Genuity Group reissued a "buy" rating and issued a $106.00 target price on shares of DexCom in a report on Friday, August 1st. William Blair upgraded DexCom to a "strong-buy" rating in a research note on Thursday, July 31st. Finally, Truist Financial began coverage on shares of DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $99.89.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.